Compare Mabion SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
PLN 132 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.04
-85.35%
1.88
Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Sep 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.63%
0%
28.63%
6 Months
2.64%
0%
2.64%
1 Year
-12.01%
0%
-12.01%
2 Years
-45.15%
0%
-45.15%
3 Years
-47.84%
0%
-47.84%
4 Years
-69.75%
0%
-69.75%
5 Years
-89.69%
0%
-89.69%
Mabion SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
73.69%
EBIT Growth (5y)
-0.13%
EBIT to Interest (avg)
-4.49
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.74
Tax Ratio
60.59%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.52%
ROE (avg)
28.14%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.70
EV to EBIT
-2.06
EV to EBITDA
-2.43
EV to Capital Employed
1.79
EV to Sales
11.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-86.62%
ROE (Latest)
-80.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
4.10
3.30
24.24%
Operating Profit (PBDIT) excl Other Income
-8.70
-12.10
28.10%
Interest
0.20
0.20
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-10.80
-15.40
29.87%
Operating Profit Margin (Excl OI)
-2,693.70%
-4,434.20%
174.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 24.24% vs 22.22% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 29.87% vs -0.65% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
69.00
151.70
-54.52%
Operating Profit (PBDIT) excl Other Income
1.10
74.40
-98.52%
Interest
3.10
1.20
158.33%
Exceptional Items
0.00
-12.20
100.00%
Consolidate Net Profit
-6.30
41.30
-115.25%
Operating Profit Margin (Excl OI)
-109.70%
442.90%
-55.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -54.52% vs -7.50% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -115.25% vs 78.02% in Dec 2023
About Mabion SA 
Mabion SA
Pharmaceuticals & Biotechnology
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Company Coordinates 
Company Details
Ul. gen. Mariana Langiewicza 60 , KONSTANTYNOW LODZKI None : 95-050
Registrar Details






